David Beidler
Overview
Explore the profile of David Beidler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soderstrom C, Larsen J, Owen C, Gifondorwa D, Beidler D, Yong F, et al.
AAPS J
. 2022 Dec;
25(1):12.
PMID: 36539515
Duchenne muscular dystrophy (DMD) is a degenerative muscular disease affecting roughly one in 5000 males at birth. The disease is often caused by inherited X-linked recessive pathogenic variants in the...
2.
Pittman D, Hines P, Beidler D, Rybin D, Frelinger A, Michelson A, et al.
Blood
. 2020 Oct;
137(15):2010-2020.
PMID: 33067606
Clinical trials in sickle cell disease (SCD) often focus on health care utilization for painful vaso-occlusive crises (VOCs). However, no objective, quantifiable pain biomarkers exist, pain is not specific to...
3.
Charnigo R, Beidler D, Rybin D, Pittman D, Tan B, Howard J, et al.
Clin Transl Sci
. 2019 Jan;
12(2):180-188.
PMID: 30597771
This phase Ib study randomized patients with stable sickle cell disease (SCD) aged 18-65 years to twice-daily PF-04447943 (a phosphodiesterase 9A inhibitor; 5 or 25 mg) or placebo, with/without hydroxyurea...
4.
Barve R, Zack M, Weiss D, Song R, Beidler D, Head R
Cytokine
. 2013 May;
63(1):10-17.
PMID: 23684409
CSF-1 is the well-known ligand for CSF-1R, which plays a vital role in monocyte-macrophage generation, survival, and function. IL-34 is a newly discovered cytokine that also signals through CSF-1R. Although...
5.
Plummer M, Cornicelli J, Roark H, Skalitzky D, Stankovic C, Bove S, et al.
Bioorg Med Chem Lett
. 2013 Apr;
23(11):3443-7.
PMID: 23597790
Selective phosphodiesterase 2 (PDE2) inhibitors are shown to have efficacy in a rat model of osteoarthritis (OA) pain. We identified potent, selective PDE2 inhibitors by optimizing residual PDE2 activity in...
6.
Plummer M, Cornicelli J, Roark H, Skalitzky D, Stankovic C, Bove S, et al.
Bioorg Med Chem Lett
. 2013 Apr;
23(11):3438-42.
PMID: 23582272
We identified potent, selective PDE2 inhibitors by optimizing residual PDE2 activity in a series of PDE4 inhibitors, while simultaneously minimizing PDE4 activity. These newly designed PDE2 inhibitors bind to the...
7.
Meyers M, Long S, Pelc M, Wang J, Bowen S, Walker M, et al.
Bioorg Med Chem Lett
. 2011 Sep;
21(21):6538-44.
PMID: 21924614
Herein we report the identification of two new fatty acid amide hydrolase (FAAH) inhibitor lead series with FAAH k(inact)/K(i) potency values greater than 1500M(-1)s(-1). The two novel spirocyclic cores, 7-azaspiro[3.5]nonane...
8.
Meyers M, Long S, Pelc M, Wang J, Bowen S, Schweitzer B, et al.
Bioorg Med Chem Lett
. 2011 Sep;
21(21):6545-53.
PMID: 21924613
Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase responsible for the degradation of fatty acid amide signaling molecules such as endocannabinoid anandamide (AEA), which has been shown...
9.
Johnson D, Stiff C, Lazerwith S, Kesten S, Fay L, Morris M, et al.
ACS Med Chem Lett
. 2011 Jun;
2(2):91-96.
PMID: 21666860
Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of...
10.
Ahn K, Smith S, Liimatta M, Beidler D, Sadagopan N, Dudley D, et al.
J Pharmacol Exp Ther
. 2011 Apr;
338(1):114-24.
PMID: 21505060
The endogenous cannabinoid (endocannabinoid) anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH). Pharmacological blockade of FAAH has emerged as a potentially attractive strategy for...